Philips expands interventional oncology portfolio with EmboGuide to see, reach and treat tumor lesions

May 15, 2014

  • New live 3D image guidance tool enhances tumor embolization procedures on Philips’ interventional X-ray systems
  • Philips Innovations detect more than twice as many tumor feeding arteries compared to standard DSA [3] while lesion detection is superior to standard DSA [1] and now comparable to gold standard contrast enhanced MRi [2].


Singapore – Royal Philips (NYSE: PHG; AEX: PHI) today announced the launch of EmboGuide, its latest innovation in interventional oncology, to support the increasing number of minimally-invasive procedures to treat difficult-to-reach tumors or tumors in patients who are deemed unsuitable for surgery. The EmboGuide will be on display from today till 18th May at the Asia-Pacific Congress of Cardiovascular and Interventional Radiology (APCCVIR) here in Singapore.


EmboGuide is a live 3D image guidance tool that supports the increasing number of minimally-invasive procedures.  It is designed for use in conjunction with Philips’ interventional X-ray system to perform tumor embolization procedures. Such procedures involve blocking the arteries feeding a tumor to deprive it of nutrients and oxygen. They require the insertion of a catheter, which must be guided to the tumor site with the aid of live image-guidance.


Developed in collaboration with leading clinicians and partners such as BTG, an innovator in interventional oncology, EmboGuide addresses the need for an enhanced 3D imaging solution to make interventional oncology procedures more effective and easier to perform, and ultimately improve patient outcomes. It offers interventional radiologists the ability to visualize and characterize tumor lesions and plan and execute interventional procedures.


"Interventional oncology is a fast growing field that offers clinicians a viable treatment option for patients who are not suitable for surgical tumor removal," says Arjen Radder, President Philips Healthcare Asia Pacific. "Together with our partners, we will leverage our combined expertise in image-guided interventions and therapies to accelerate this transformation from surgical procedures to minimally-invasive treatments in oncology."


A specific example of a tumor embolization procedure is transarterial chemo-embolization (TACE), used for palliative treatment of liver tumors. It involves simultaneous local administration of chemotherapy and beads that block the arteries feeding the liver tumor.


"We can only treat what we see, yet the embolization of all blood vessels that feed the liver tumor lesion is key for an effective TACE procedure," says Shiro Miyayama, MD, Department of Diagnostic Radiology, Fukuiken Saisekai Hospital, Japan. "EmboGuide’s live 3D image guidance helps to improve the technical success of the procedure, as it can automatically identify the small tumor-feeders that are difficult to detect with conventional 2D angiographic imaging methods."


EmboGuide leverages the ultra-low X-ray dose settings of Philips’ AlluraClarity interventional X-ray system and the fast, high quality imaging of the abdomen of XperCT Dual. XperCT Dual’s enhanced imaging technique (multiphase cone beam CT) offers high quality 3D images of lesions, with proven detection accuracy superior to conventional 2D angiographic imaging. It offers clinicians a better view of the treatment targets for informed decision making while performing the procedure. XperCT Dual is comparable to MRI, which is considered to be the ‘gold standard’ [1,2].


EmboGuide helps to define the tumor lesions and features automatic identification of blood vessels that feed the lesions. It detects more than twice as many tumor feeding arteries compared to conventional imaging methods (Digital Subtraction Angiography (DSA) [3]. This allows interventional radiologists to optimize the catheter locations for embolization and plan a route to them. During the administration of the embolization agent, EmboGuide accurately superimposes the planning information onto the interventional X-ray system’s live images to monitor the treatment progress and determine its endpoint [4-6].


"In the treatment of intermediate HCC, the integrated use of our embolic device with image guidance is vital for successful treatment" says Mike Motion, BTG General Manager, Interventional Oncology.  "As a leader in interventional oncology, we invest to improve the safety and efficacy of the procedure. Partnering with Philips has strengthened our ability to further develop this cohesive approach using DC Bead® and Philips’ EmboGuide with the ultimate objective of advancing interventional oncology."


The launch of EmboGuide is a result of Philips’ global investment in Healthcare R&D, which amounted to a total of EUR 780 million in 2013. It highlights Philips’ commitment to interventional oncology - a rapidly developing market with a compound annual growth rate of around 15%.


At the congress, Dr. Miyayama will share his experiences with EmboGuide in a scientific presentation titled ‘Lesion detection and feeding Vessel identification in HCC with XperCT Dual and EmboGuide’.


EmboGuide is currently not available in the USA.



[1] Lesion detection for HCC with XperCT is superior to standard DSA. Miyayama et al.; J. Vasc. Interv. Radiol. 2013 Apr;24(4): 501-8. doi: 10.1016/j.jvir.2012.12.022. Epub 2013 Feb 26.
[2] DualPhase Lesion detection in HCC with XperCT is comparable to gold standard CE-MRI. Loffroy et al.; Cardiovasc Intervent Radiol. 2012 Feb;35(1):97-104. doi: 10.1007/s00270-011-0118-x. Epub 2011 Feb 17.
[3] Feeder detection up to 50% higher compared to standard DSA. Miyayama et al.; J Vasc Interv Radiol. 2013 Apr;24(4):501-8. doi: 10.1016/j.jvir.2012.12.022. Epub 2013 Feb 26.
[4] Dual Phase XperCT after DEB-TACE for HCC can be used to predict tumor response at 1-month MRI. Loffroy et al., Radiology, Vol.266 No.2 p.346-368, Feb. 2013
[5] Intraprocedural monitoring of lipiodol TACE with XperCT improves technical success and leads to reduced local tumor recurrence. Miyayama et al.;  Cardiovasc Intervent Radiol. 2013 Jun 19
[6] High marginal contrast saturation on XperCT after DEB-TACE is predictive of short term tumor response in HCC. Sukh et al.;  J Vasc Interv Radiol. 2013 Apr;24(4):483-9. doi: 10.1016/j.jvir.2013.01.001. Epub 2013 Feb 26.

For further information, please contact:

Christina Celestine
Tel.: +65 8518 5479


Steve Klink 
Philips Group Communications
Tel.: +31 6 1088 8824


About Royal Philips:

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at